LEADER 00889nam2-22003011i-450- 001 990000179650403321 005 20120716110440.0 035 $a000017965 035 $aFED01000017965 035 $a(Aleph)000017965FED01 035 $a000017965 100 $a20020821d--------km-y0itay50------ba 101 0 $aita 105 $ay-------001yy 200 1 $a3. : Villas suburbaines 210 $aParis$cChez A. Morel et C.$d1864- 215 $av.$e74 tav.$cill.$d45 cm 461 0$1001000013438$12001$a<>architecture privée au 19. siècle sous Napoleon III 610 0 $aParigi$aDintorni$aVille$aSec. 19 676 $a728.840 944 36 700 1$aDaly,$bCésar M.$f<1811-1893> 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000179650403321 952 $a13 AR 30 D 37$b22118$fFINBC 952 $a13 AR 9 C 12$b17815$fFINBC 959 $aFINBC 997 $aUNINA LEADER 02882nam 2200817z- 450 001 9910557114503321 005 20231214133626.0 035 $a(CKB)5400000000040901 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69079 035 $a(EXLCZ)995400000000040901 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aOutcomes and Therapeutic Management of Bladder Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (120 p.) 311 $a3-03936-934-2 311 $a3-03936-935-0 330 $aBladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease. 606 $aMedicine$2bicssc 610 $abladder cancer 610 $arobotic-assisted 610 $aopen 610 $aradical cystectomy 610 $asurvival 610 $apropensity score 610 $aage 610 $aurothelial carcinoma 610 $aoutcome 610 $aanesthesia recovery periods 610 $acognitive impairment 610 $agamma-cyclodextrins 610 $aneuromuscular blockade 610 $arobotic radical cystectomy 610 $aglycogen 610 $aclear-cell adenocarcinoma 610 $aurinary bladder 610 $aSEER program database 610 $afemale 610 $aintracorporeal neobladder 610 $aoutcomes 610 $arobotic 610 $asex-sparing 610 $amethylation 610 $abiomarkers 610 $aFOXA1 610 $aGATA3 610 $aKRT20 610 $amolecular markers 610 $amRNA 610 $amuscle-invasive bladder cancer 610 $aPCR 610 $ahuman epidermal growth factor receptor 2 610 $aindoleamine 2,3-dioxygenase 610 $aprogrammed death ligand-1 610 $aimmunotherapy 610 $anodal disease 610 $apN1 610 $aneoadjuvant 610 $aadjuvant 610 $achemotherapy 615 7$aMedicine 700 $aMoschini$b Marco$4edt$0481847 702 $aMoschini$b Marco$4oth 906 $aBOOK 912 $a9910557114503321 996 $aOutcomes and Therapeutic Management of Bladder Cancer$93038144 997 $aUNINA